We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Primary Health Properties plc (PHP) Ordinary Shares 12.5p

Sell:90.65p Buy:91.00p 0 Change: 2.45p (2.63%)
FTSE 250:0.41%
Market closed Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:90.65p
Buy:91.00p
Change: 2.45p (2.63%)
Market closed Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:90.65p
Buy:91.00p
Change: 2.45p (2.63%)
Market closed Prices as at close on 24 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

HL comment (28 February 2024)

Full-year net rental income rose 5.5% to £149.3mn. Rent reviews contributed to £4.0mn in additional rent over the year, with a smaller contribution coming from extensions and refurbishments. Underlying profit rose 2.3% to £90.7mn.

The value of the investment portfolio fell 1.9% to £2.8bn, due to rising yields. With only one development underway, exposure to higher build costs is limited. Occupancy was at 99.3% at the end of the year.

Net debt was broadly flat at £1.3bn, with a loan-to-value of 47.0% (target 40-50%). On 23 February, the first quarterly interim dividend of 1.725p was paid, up 3%.

In the near future, growth is set to be focused on developing the existing portfolio. Ireland is the preferred area for future investment, with ambitions to grow the portfolio to 15% of total assets (currently 9%).

The shares were flat in early trading.

Our View

Primary Health Properties' purpose-built doctor's surgeries have a long track record of delivering results for shareholders and is now in its 28th consecutive year of dividend increases. As a REIT (real estate investment trust), PHP has to pay out the vast majority of profits as a dividend.

PHP has successfully navigated the interest rate rises seen over the past year or so. But there has been an impact on the portfolio value as well as the investment market, largely relating to a lack of transactions as potential buyers try to wait out the higher-rate environment. That, plus the higher cost of capital, means PHP is relatively underweight in the development arena for now. Instead, it's focused on squeezing more from existing locations, where it sees further upside.

We like the move. Performance over the past couple of years has been diven by rent hikes. Those same elevated costs, and the lack of new supply, are giving landlords like PHP more bargaining power at the negotiating table.

Looking to the future, we think PHP has several features that underpin long-term dividend-paying potential. The backlog of procedures in the NHS and the needs of an ageing population means investment in primary care facilities isn't going anywhere.

And, with 89% of the group's rent roll funded by the NHS or its Irish equivalent, we view the group's tenants as lower risk. An average lease length of 10 years should mean rental income is secure for years to come.

There are some reasons for caution too though. Loan-to-value (LTV) is high by industry standards, and has risen over the past year as property values have fallen. Plus, the group's REIT structure also means investors are likely to be asked to fork out extra cash from time-to-time, especially as debt financing remains expensive for now. Because REITs have to pay out most of their profits it's difficult for them to fund growth organically.

PHP's valuation isn’t overly demanding and the prospective dividend yield is attractive, though nothing is guaranteed. Mark Davies will take over as CEO in April, but shouldn't impact the overall strategy and we continue to like PHP as a play on a resilient segment of the UK property market. However, we caution that there remains a risk of falling property values if rates stay higher for longer.

Primary Health Properties key facts

  • Forward price/book ratio (next 12 months): 0.98

  • Ten year average forward price/book ratio: 1.17

  • Prospective dividend yield (next 12 months): 7.7%

  • Ten year average prospective dividend yield: 5.0%

All ratios are sourced from Refinitiv, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.

Important information - This article isn’t personal advice. If you’re not sure whether an investment is right for you please seek advice. If you choose to invest the value of your investment will rise and fall, so you could get back less than you put in.

This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.


Previous Primary Health Properties plc updates

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.